Sex, age, and time to cardioversion. Risk factors for cardioversion of acute atrial fibrillation from the FinCV study

References

• Camm A, Lip G, De Caterina R, Savelieva I, Atar D, Hohnloser S, et al. 2012 guidelines for the management of atrial fibrillation. The task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2012;33:2719–49.
   PubMed Web of Science ®Google Scholar
• Bushnell C, McCullough L, Awad I, Chireau M, Fedder W, Furie K, et al. Guidelines for the prevention of stroke in women: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45:1545–88.
   PubMed Web of Science ®Google Scholar
• Abraham J, Larson J, Chung M, Curtis A, Lakshminarayan K, Newman J, et al. Does CHA2DS2-VASc improve stroke risk stratification in postmenopausal women with atrial fibrillation? Am J Med. 2013;126:1148–53.
   Web of Science ®Google Scholar
• Friberg L, Benson L, Rosenqvist M, Lip G. Assessment of female sex as a risk factor in atrial fibrillation in Sweden: nationwide retrospective cohort study. BMJ. 2012;344:3522.
   PubMed Web of Science ®Google Scholar
• Olesen J, Lip G, Hansen M, Hansen P, Tolstrup J, Lindhardsen J, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ. 2011;342:d124.
   PubMed Web of Science ®Google Scholar
• Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, et al. Heart disease and stroke statistics—2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117:25–146.
   PubMed Web of Science ®Google Scholar
• Kleemann T, Becker T, Strauss M, Schneider S, Seidl K. Prevalence of left atrial thrombus and dense spontaneous echo contrast in patients with short-term atrial fibrillation, <48 hours undergoing cardioversion: value of transesophageal echocardiography to guide cardioversion. J Am Soc Echocardiogr. 2009;22:1403–8.
   PubMed Web of Science ®Google Scholar
• Airaksinen J, Grönberg T, Nuotio I, Nikkinen M, Ylitalo A, Biancari F, et al. Thromboembolic complications after cardioversion of acute atrial fibrillation. The FinCV (Finnish CardioVersion) study. J Am Coll Cardiol. 2013;62:1187–92.
   PubMed Web of Science ®Google Scholar
• Nuotio I, Hartikainen J, Grönberg T, Biancari F, Airaksinen J. Time to cardioversion for acute atrial fibrillation and thromboembolic complications. JAMA. 2014;312:647–9.
   PubMed Web of Science ®Google Scholar
• Cappato R, Ezekowitz MD, Klein L, Camm J, Chang-Sheng M, Le Heuzey JY, on behalf of the X-VeRT Investigators, et al. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J. 2014;35:3346–55.
   PubMed Web of Science ®Google Scholar
• Nagarakanti R, Ezekowitz MD, Oldgren J, Yang S, Chernick M, Aikens TH, et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation. 2011;123:131–6.
   PubMed Web of Science ®Google Scholar
• Flaker G, Lopes R, Al-Khatib S, Hermosillo A, Hohnloser S, Tinga B, for the ARISTOTLE Committees and Investigators, et al. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation insights from the ARISTOTLE trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). J Am Coll Cardiol. 2014;63:1082–7.
   PubMed Web of Science ®Google Scholar
• Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC endorsed by the European Stroke Organisation (ESO). Eur Heart J. 2016;37:2893–962.
   PubMed Web of Science ®Google Scholar
• Azoulay L, Dell’Aniello S, Simon T, Renoux C, Suissa S. Initiation of warfarin in patients with atrial fibrillation: early effects on ischaemic strokes. Eur Heart J. 2014;35:1881–7.
   PubMed Web of Science ®Google Scholar
• Linhart M, Lewalter T. Elektrische und pharmakologische Frühkardioversion von Vorhofflimmern [Electrical and pharmacological strategies for early cardioversion of atrial fibrillation]. Herzschrittmacherther Elektrophysiol. 2006;17:81–8.
   PubMedGoogle Scholar
• Sohara H, Amitani S, Kurose M, Miyahara K. Atrial fibrillation activates platelets and coagulation in a time-dependent manner: a study in patients with paroxysmal atrial fibrillation. J Am Coll Cardiol. 1997;29:106–12.
   PubMed Web of Science ®Google Scholar
• Rienstra M, Van Veldhuisen D, Hagens V, Ranchor A, Veeger N, Crijns H, et al. Gender-related differences in rhythm control treatment in persistent atrial fibrillation: data of the Rate Control Versus Electrical Cardioversion (RACE) study. J Am Coll Cardiol. 2005;46:1298–306.
   PubMed Web of Science ®Google Scholar
• Grönberg T, Hartikainen J, Nuotio I, Biancari F, Vasankari T, Nikkinen M, et al. Can we predict the failure of electrical cardioversion of acute atrial fibrillation? The FinCV study. Pacing Clin Electrophysiol. 2014;38:368–75.
   PubMed Web of Science ®Google Scholar